Evidence map›Paper›PMID 25363635›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2015

Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.

Nancy E Joste, Brigitte M Ronnett, William C Hunt, Amanda Pearse, Erika Langsfeld, Thomas Leete, MaryAnn Jaramillo, Mark H Stoler, Philip E Castle, Cosette M Wheeler and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Differential Risk of Cervical Cancer in HPV-Vaccinated and -Unvaccinated Women: A Mathematical Modeling Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nancy E JosteDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members).
Brigitte M RonnettDepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland.
William C HuntDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members).
Amanda PearseDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
Erika LangsfeldDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
Thomas LeeteDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
MaryAnn JaramilloDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members).
Mark H StolerNew Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members). Department of Pathology, University of Virginia, Charlottesville, Virginia.
Philip E CastleNew Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members). Global Cancer Initiative, Chestertown, Maryland.
Cosette M WheelerDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members). Department of Obstetrics and Gynecology, House of Prevention Epidemiology (HOPE), University of New Mexico Health Sciences Center, Albuquerque, New Mexico. cwheeler@salud.unm.edu.
New Mexico HPV Pap Registry Steering Committee
University of Virginia · US

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Web enhanced adoption of HPV vaccine in minority communitiesU19AI084081 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI STIDLEY, CHRISTINE A. · 2009 to 2013
$13.4M
NCI NIH HHS P30 CA118100NIAID NIH HHS U19 AI084081NIAID NIH HHS U19AI084081
6 · The paper itself

Abstract

backgroundThe New Mexico HPV Pap Registry was established to measure the impact of cervical cancer prevention strategies in the United States. Before widespread human papillomavirus (HPV) vaccine implementation, we established the baseline prevalence for a broad spectrum of HPV genotypes across the continuum of cervical intraepithelial neoplasia (CIN) and cancer.

methodsA population-based sample of 6,272 tissue specimens was tested for 37 HPV genotypes. The number of specimens tested within each diagnostic category was: 541 negative, 1,411 CIN grade 1 (CIN1), 2,226 CIN grade 2 (CIN2), and 2,094 CIN grade 3 (CIN3) or greater. Age-specific HPV prevalence was estimated within categories for HPV genotypes targeted by HPV vaccines.

resultsThe combined prevalence of HPV genotypes included in the quadrivalent and nonavalent vaccines increased from 15.3% and 29.3% in CIN1 to 58.4% and 83.7% in CIN3, respectively. Prevalence of HPV types included in both vaccines tended to decrease with increasing age for CIN1, CIN2, CIN3, and squamous cell carcinoma (SCC), most notably for CIN3 and SCC. The six most common HPV types in descending order of prevalence were HPV-16, -31, -52, -58, -33, and -39 for CIN3 and HPV-16, -18, -31, -45, -52, and -33 for invasive cancers.

conclusionsHealth economic modeling of HPV vaccine impact should consider age-specific differences in HPV prevalence. IMPACT: Population-based HPV prevalence in CIN is not well described, but is requisite for longitudinal assessment of vaccine impact and to understand the effectiveness and performance of various cervical screening strategies in vaccinated and unvaccinated women.

Indexed as

AdolescentAdultAgedAged, 80 and overFemaleGenotypeHumansMiddle AgedNeoplasmsPapillomaviridaePapillomavirus InfectionsPrevalenceRisk FactorsUterine Cervical NeoplasmsYoung Adult

Identifiers

PMID25363635
PMCPMC4294978
OpenAlexW2167291269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.